Short answer: Each page compares two compounds side by side: mechanism, approval status, label dosing (or what studies used), half-life, time to peak, strengths and warnings, with sources. Among GLP-1s, tirzepatide beat semaglutide head to head (−20.2% vs −13.7% at 72 weeks)1; retatrutide is not yet approved.
Approved drugs are described from their FDA labels. Research compounds are described only from published studies, and none of it is a dose recommendation. Half-lives are shown only where the value Dose Track uses agrees with the cited source.
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Approval status | FDA approved (Ozempic, Wegovy) | FDA approved (Mounjaro, Zepbound) | Investigational; BLA planned Q1 20272 |
| Starting dose | 0.25 mg weekly (label)3 | 2.5 mg weekly (label)4 | 2 mg weekly (phase 3 trials)5 |
| Highest dose | 2.4 mg (7.2 mg Wegovy HD) | 15 mg | 12 mg in trials |
| Half-life | about 7 days | about 5 days | about 6 days6 |
| Frequency | Weekly (tablet daily) | Weekly | Weekly in trials |
| Pivotal weight result | −13.7% at 72 weeks (SURMOUNT-5)1 | −20.2% at 72 weeks (SURMOUNT-5)1 | −28.3% at 80 weeks, 12 mg (TRIUMPH-1, efficacy estimand)7 |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors | No label yet |
Semaglutide and tirzepatide were compared in the same trial; retatrutide was not, so its number is not directly comparable. More detail: Semaglutide vs tirzepatide: what did the head-to-head trial show?, Retatrutide vs tirzepatide: how do they compare?.